Kanayama Seiji, Nakagawa Eriko, Ueno Sayaka, Muraji Miho, Wakahashi Senn, Sudo Tamotsu, Yamada Takashi, Yamaguchi Satoshi, Fujiwara Kiyoshi, Nishimura Ryuichiro
Department of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kita-Oji, Akashi, Hyogo 673-8558, Japan.
World J Oncol. 2014 Apr;5(2):62-67. doi: 10.14740/wjon799w. Epub 2014 May 6.
Currently, there is no standardized follow-up protocol for patients who undergo laser conization. Therefore, we retrospectively investigated the clinical outcomes of laser conization in patients with high-grade cervical intraepithelial neoplasia 2-3 (CIN 2-3) and microinvasive squamous cell carcinoma and assessed the risks of residual and recurrent lesions of the cervix uteri.
The medical and pathological records of 91 patients with CIN 2, 580 with CIN 3 and 73 with microinvasive cervical cancer (MIC) who underwent laser conization between January 2000 and December 2011 were retrospectively reviewed.
Positive margins increased with the extent of disease and were observed in 5.5%, 8.9% and 16.4% patients with CIN 2, CIN 3 and MIC, respectively, while residual or recurrent disease was observed in 0%, 3.2% and 13.6% patients, respectively. Examination of specimens obtained through postconization biopsy or hysterectomy revealed that 1.5% and 20% patients with negative and positive margins, respectively, were diagnosed with residual or recurrent lesions. Among patients who were conservatively managed after conization, seven with CIN 3 exhibited residual or recurrent disease, as evidenced by abnormal cytological findings, within 2 years after conization.
Continuous follow-up by cytology and colposcopy, particularly during the first 2 years after conization, can effectively detect early residual or recurrent disease in CIN 3 and MIC patients, regardless of their margin status.
目前,对于接受激光锥切术的患者尚无标准化的随访方案。因此,我们回顾性研究了高级别宫颈上皮内瘤变2-3级(CIN 2-3)和微浸润性鳞状细胞癌患者激光锥切术的临床结局,并评估了子宫颈残留和复发病变的风险。
回顾性分析2000年1月至2011年12月期间接受激光锥切术的91例CIN 2患者、580例CIN 3患者和73例微浸润性宫颈癌(MIC)患者的医学和病理记录。
切缘阳性率随疾病程度增加,CIN 2、CIN 3和MIC患者的切缘阳性率分别为5.5%、8.9%和16.4%,而残留或复发病例分别为0%、3.2%和13.6%。通过锥切术后活检或子宫切除获得的标本检查显示,切缘阴性和阳性的患者中分别有1.5%和20%被诊断为残留或复发病变。在锥切术后接受保守治疗的患者中,7例CIN 3患者在锥切术后2年内出现细胞学异常,提示残留或复发病变。
通过细胞学和阴道镜进行持续随访,尤其是在锥切术后的前2年,无论切缘状态如何,都能有效检测CIN 3和MIC患者的早期残留或复发病变。